2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·19 min sitten · MuokattuTrading activity has recently been far below the average for the year. Of course, many are holding back on new investments until 21/9 when there is a Capital Markets Day. This has left a vacuum where speculators, short sellers, algorithms have been able to affect the price very negatively on low volume, as they know investors are hesitant ahead of strategic announcements on 21/9 Volume has in no way shown that shareholders just wanted out. We have seen what that looks like! there is volume 10 x higher than it has been during the recent declines. That's how I see it👍 Facts: The latest trading week we just ended with significant declines, the daily trading volume has been well over 8 million on average in the USA, compared to the daily average over the last year, of just over 17 million.
Novo just screams buy at this level. Just a matter of time before we are back at 500+
·43 min sittenOne has become quite thick-skinned from being in Novo by now - from being like Sofie Gråbøl in Blinkende Lygter with a bloody nose exclaiming: "what happened?" to - oh well, just another day under 300💩
·1 t sittenCryptic Novo message: 'Exciting update on the next chapter' https://ekstrabladet.dk/penge/kryptisk-novo-melding-spaende-opdatering-om-naeste-kapitel/11286281?utm_term=Autofeed&utm_medium=Social&utm_source=Facebook&fbclid=IwY2xjawURvdtwZG9mBWV4dG4DYWVtAjEwAGJyaWQRMTlyTUE3Q0lQaEhSZTJSRXhzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEe1VgyvHvPqYY-d4AjiUC16MIT9WFBcm7UhaJ0tehujl9s8jTteBZsYlxP0no_aem_PZxhqUCz6djh-D7G5AaLVw#Echobox=1789140862Likely a message to the employees that when revenue is halved in 5 years, then the next chapter is that half of them change career paths 😵💫- ·3 t sittenMIM8, Amycretin, CagriSema and MASH Novo Nordisk is building a strong new portfolio of medicines – including Mim8 for hemophilia, semaglutide for the liver disease MASH, as well as the next generation of weight-loss medicines CagriSema and Amycretin – which are designed to generate billions of dollars in new revenue. These treatments expand the company's reach far beyond traditional diabetes treatment and into enormous, as yet untapped medical markets, as well as within rare diseases. Although fierce competition from Eli Lilly means that weight-loss medicines like CagriSema face a tougher battle for market dominance, this diversified portfolio serves as a strategic protection. Collectively, these blockbuster drugs are expected to generate double-digit billions in annual sales at their peak, which will ensure that Novo Nordisk remains a highly profitable global pharmaceutical giant for many years to come. Expected revenues Overall, this specific group of new medicines is estimated to generate approximately 23–25 billion dollars in annual revenues for Novo Nordisk by 2030. To put that into perspective, these new medicines alone will account for almost 30 % of Novo Nordisk's expected total revenue of 84 billion dollars in 2030.With those assumptions, it starts to land on something in the range of 350-425 kr. as a reasonable price “ i dag”, if the 84 billion USD in 2030 are realistic and Novo still has strong earnings thereafter. That is actually quite far from a price around 280 kr. — and that's what makes the case interesting.
·3 t sittenOh no, I had planned to use all my investment in 15 years. 🙈 Now I'm completely in doubt if Novo will ever go above 300 again. 😫
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 min sitten · MuokattuTrading activity has recently been far below the average for the year. Of course, many are holding back on new investments until 21/9 when there is a Capital Markets Day. This has left a vacuum where speculators, short sellers, algorithms have been able to affect the price very negatively on low volume, as they know investors are hesitant ahead of strategic announcements on 21/9 Volume has in no way shown that shareholders just wanted out. We have seen what that looks like! there is volume 10 x higher than it has been during the recent declines. That's how I see it👍 Facts: The latest trading week we just ended with significant declines, the daily trading volume has been well over 8 million on average in the USA, compared to the daily average over the last year, of just over 17 million.Novo just screams buy at this level. Just a matter of time before we are back at 500+
- ·43 min sittenOne has become quite thick-skinned from being in Novo by now - from being like Sofie Gråbøl in Blinkende Lygter with a bloody nose exclaiming: "what happened?" to - oh well, just another day under 300💩
- ·1 t sittenCryptic Novo message: 'Exciting update on the next chapter' https://ekstrabladet.dk/penge/kryptisk-novo-melding-spaende-opdatering-om-naeste-kapitel/11286281?utm_term=Autofeed&utm_medium=Social&utm_source=Facebook&fbclid=IwY2xjawURvdtwZG9mBWV4dG4DYWVtAjEwAGJyaWQRMTlyTUE3Q0lQaEhSZTJSRXhzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEe1VgyvHvPqYY-d4AjiUC16MIT9WFBcm7UhaJ0tehujl9s8jTteBZsYlxP0no_aem_PZxhqUCz6djh-D7G5AaLVw#Echobox=1789140862Likely a message to the employees that when revenue is halved in 5 years, then the next chapter is that half of them change career paths 😵💫
- ·3 t sittenMIM8, Amycretin, CagriSema and MASH Novo Nordisk is building a strong new portfolio of medicines – including Mim8 for hemophilia, semaglutide for the liver disease MASH, as well as the next generation of weight-loss medicines CagriSema and Amycretin – which are designed to generate billions of dollars in new revenue. These treatments expand the company's reach far beyond traditional diabetes treatment and into enormous, as yet untapped medical markets, as well as within rare diseases. Although fierce competition from Eli Lilly means that weight-loss medicines like CagriSema face a tougher battle for market dominance, this diversified portfolio serves as a strategic protection. Collectively, these blockbuster drugs are expected to generate double-digit billions in annual sales at their peak, which will ensure that Novo Nordisk remains a highly profitable global pharmaceutical giant for many years to come. Expected revenues Overall, this specific group of new medicines is estimated to generate approximately 23–25 billion dollars in annual revenues for Novo Nordisk by 2030. To put that into perspective, these new medicines alone will account for almost 30 % of Novo Nordisk's expected total revenue of 84 billion dollars in 2030.With those assumptions, it starts to land on something in the range of 350-425 kr. as a reasonable price “ i dag”, if the 84 billion USD in 2030 are realistic and Novo still has strong earnings thereafter. That is actually quite far from a price around 280 kr. — and that's what makes the case interesting.
- ·3 t sittenOh no, I had planned to use all my investment in 15 years. 🙈 Now I'm completely in doubt if Novo will ever go above 300 again. 😫
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
38 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,09%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 min sitten · MuokattuTrading activity has recently been far below the average for the year. Of course, many are holding back on new investments until 21/9 when there is a Capital Markets Day. This has left a vacuum where speculators, short sellers, algorithms have been able to affect the price very negatively on low volume, as they know investors are hesitant ahead of strategic announcements on 21/9 Volume has in no way shown that shareholders just wanted out. We have seen what that looks like! there is volume 10 x higher than it has been during the recent declines. That's how I see it👍 Facts: The latest trading week we just ended with significant declines, the daily trading volume has been well over 8 million on average in the USA, compared to the daily average over the last year, of just over 17 million.Novo just screams buy at this level. Just a matter of time before we are back at 500+
- ·43 min sittenOne has become quite thick-skinned from being in Novo by now - from being like Sofie Gråbøl in Blinkende Lygter with a bloody nose exclaiming: "what happened?" to - oh well, just another day under 300💩
- ·1 t sittenCryptic Novo message: 'Exciting update on the next chapter' https://ekstrabladet.dk/penge/kryptisk-novo-melding-spaende-opdatering-om-naeste-kapitel/11286281?utm_term=Autofeed&utm_medium=Social&utm_source=Facebook&fbclid=IwY2xjawURvdtwZG9mBWV4dG4DYWVtAjEwAGJyaWQRMTlyTUE3Q0lQaEhSZTJSRXhzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEe1VgyvHvPqYY-d4AjiUC16MIT9WFBcm7UhaJ0tehujl9s8jTteBZsYlxP0no_aem_PZxhqUCz6djh-D7G5AaLVw#Echobox=1789140862Likely a message to the employees that when revenue is halved in 5 years, then the next chapter is that half of them change career paths 😵💫
- ·3 t sittenMIM8, Amycretin, CagriSema and MASH Novo Nordisk is building a strong new portfolio of medicines – including Mim8 for hemophilia, semaglutide for the liver disease MASH, as well as the next generation of weight-loss medicines CagriSema and Amycretin – which are designed to generate billions of dollars in new revenue. These treatments expand the company's reach far beyond traditional diabetes treatment and into enormous, as yet untapped medical markets, as well as within rare diseases. Although fierce competition from Eli Lilly means that weight-loss medicines like CagriSema face a tougher battle for market dominance, this diversified portfolio serves as a strategic protection. Collectively, these blockbuster drugs are expected to generate double-digit billions in annual sales at their peak, which will ensure that Novo Nordisk remains a highly profitable global pharmaceutical giant for many years to come. Expected revenues Overall, this specific group of new medicines is estimated to generate approximately 23–25 billion dollars in annual revenues for Novo Nordisk by 2030. To put that into perspective, these new medicines alone will account for almost 30 % of Novo Nordisk's expected total revenue of 84 billion dollars in 2030.With those assumptions, it starts to land on something in the range of 350-425 kr. as a reasonable price “ i dag”, if the 84 billion USD in 2030 are realistic and Novo still has strong earnings thereafter. That is actually quite far from a price around 280 kr. — and that's what makes the case interesting.
- ·3 t sittenOh no, I had planned to use all my investment in 15 years. 🙈 Now I'm completely in doubt if Novo will ever go above 300 again. 😫
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 785 | - | - | ||
| 135 | - | - | ||
| 9 150 | - | - | ||
| 200 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt